Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPRI cell plus postoperative chemotherapy in resected non-small cell lung cancer
ChiCTR1800019904Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Mar 2019
- Modality
- Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of CAPRI cell in non-small cell lung cancer (NSCLC) (2 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoints: progression-free survival, serious adverse event rate and 1 more. Planned start Mar 2019; status: not yet recruiting.
02
Drugs
CAPRI cell
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1800019904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019904.